

**Certificate of Approval of a Prospectus
pursuant to Prospectus Regulation (EU) 2017/1129 of the European Parliament and of the
Council Certificate Reference [364139]**

To: Financial Services and Markets Authority, Belgium

From: Financial Conduct Authority, United Kingdom

We hereby certify that the Prospectus detailed below has been drawn up pursuant to Prospectus Regulation (EU) 2017/1129 of the European Parliament and of the Council and was approved by us on 14th August 2020.

Name of Issuer(s): Acacia Pharma Group plc

LEI: 213800SLDKXWKT6E3381

Registered Office(s): England and Wales

Type of Securities (if applicable): Issue of 12,500,000 New Ordinary Shares and Admission of the New Ordinary Shares to trading on the regulated market of Euronext Brussels

National Prospectus Identifier: PRO05368

(references to the annexes of Regulation used): Annexes 3 & 12

Name of the Guarantor(s) (if any): N/A

We have authorised, in accordance with Article 18 of Prospectus Regulation (EU) 2017/1129, the omission of the information required on the following grounds: **[No omission]**

FCA Stamp:

Financial Conduct Authority
Document Approved

Date: 14/08/2020

Signed:.....

A handwritten signature in black ink, consisting of a stylized 'G' followed by a long horizontal stroke.

For and on behalf of the Financial Conduct Authority

Date: 14/08/2020

Attachments: (1) Prospectus